<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02710604</url>
  </required_header>
  <id_info>
    <org_study_id>CTRV-CMX157-201</org_study_id>
    <nct_id>NCT02710604</nct_id>
  </id_info>
  <brief_title>Phase 2, Multiple Ascending Dose Proof of Concept Study</brief_title>
  <official_title>A Phase 2, Randomized, Open-label, Ascending, Sequential Dose Group, Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of CMX157 in HBV-infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ContraVir Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ContraVir Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2a study to evaluate the safety and tolerability of multiple oral doses of
      CMX157 at increasing dose levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2a study to evaluate the safety and tolerability of multiple oral doses of
      CMX157 at increasing dose levels in hepatitis B virus(HBV) infected subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">July 18, 2017</completion_date>
  <primary_completion_date type="Actual">July 18, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the safety and tolerability of increasing multiple oral doses of CMX157 in HBV + patients</measure>
    <time_frame>28 days</time_frame>
    <description>Capture adverse events, physical examinations, ECGs and clinical laboratory panels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the antiviral activity of CMX157 versus tenofovir disproxil fumarate(TDF).</measure>
    <time_frame>28 days</time_frame>
    <description>HBV DNA levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the pharmacokinetics of multiple doses of oral CMX157 in HBV + subjects, Cmax.</measure>
    <time_frame>28 days</time_frame>
    <description>Measuring Cmax(concentration maximum): the peak plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the pharmacokinetics of multiple doses of oral CMX157 in HBV + subjects: Tmax.</measure>
    <time_frame>28 days</time_frame>
    <description>Measuring Tmax(time maximum): the time Cmax was observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the pharmacokinetics of multiple doses of oral CMX157 in HBV + subjects: AUC.</measure>
    <time_frame>28 days</time_frame>
    <description>Measuring AUC(area under the curve): area under plasma concentration versus time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the pharmacokinetics of multiple doses of oral CMX157 in HBV + subjects: Cmin.</measure>
    <time_frame>28 days</time_frame>
    <description>Measuring Cmin(concentration minimum): minimum observed plasma concentration.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Infectious Disease</condition>
  <arm_group>
    <arm_group_label>CMX157 5mg versus TDF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CMX157, 5mg tablet, 28 days versus TDF(tenofovir disoproxil fumerate) 300mg tablet, 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CMX157 10mg versus TDF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CMX157, 10mg tablet, 28 days versus TDF 300mg tablet, 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CMX157 25mg versus TDF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CMX157, 25mg tablet, 28 days versus TDF 300mg tablet, 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CMX157 50mg versus TDF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CMX157, 50mg tablet, 28 days versus TDF 300mg tablet, 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CMX157 100mg versus TDF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CMX157, 100mg tablet, 28 days versus TDF 300mg tablet, 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CMX157</intervention_name>
    <description>tablet</description>
    <arm_group_label>CMX157 5mg versus TDF</arm_group_label>
    <arm_group_label>CMX157 10mg versus TDF</arm_group_label>
    <arm_group_label>CMX157 25mg versus TDF</arm_group_label>
    <arm_group_label>CMX157 50mg versus TDF</arm_group_label>
    <arm_group_label>CMX157 100mg versus TDF</arm_group_label>
    <other_name>lipid conjugate TFV(tenofovir)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TDF</intervention_name>
    <description>300mg tablet</description>
    <arm_group_label>CMX157 5mg versus TDF</arm_group_label>
    <arm_group_label>CMX157 10mg versus TDF</arm_group_label>
    <arm_group_label>CMX157 25mg versus TDF</arm_group_label>
    <arm_group_label>CMX157 50mg versus TDF</arm_group_label>
    <arm_group_label>CMX157 100mg versus TDF</arm_group_label>
    <other_name>tenofovir disoproxil fumerate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capable of giving written informed consent.

          -  Capable of completing study requirements.

          -  Chronic hepatitis B positive.

          -  HBV treatment na√Øve.

        Exclusion Criteria:

          -  Positive result for HCV(hepatitis C virus), HDV(hepatitis D virus) or HIV(human
             immunodeficiency virus).

          -  History or medical condition that could impact patient safety.

          -  Current or past abuse of alcohol or illicit drugs.

          -  Abnormal laboratory value or ECG.

          -  Pregnant or breastfeeding.

          -  Clinical, histologic or laboratory evidence of significant liver fibrosis or
             cirrhosis.

          -  Systemic immunosuppression.

          -  Received an investigational drug or investigational vaccine within the 90 days prior
             to the first dose of study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Sullivan-Boylai, MD</last_name>
    <role>Study Chair</role>
    <affiliation>ContraVir Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2016</study_first_submitted>
  <study_first_submitted_qc>March 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2016</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic hepatitis B(CHB)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

